A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of YYC405-T Added to Metformin and Dapagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With the Combination of Metformin and Dapagliflozin
Latest Information Update: 07 May 2024
At a glance
- Drugs YYC 405 (Primary) ; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Yooyoung Pharmaceutical
Most Recent Events
- 30 May 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2022 New trial record